@Article{,
AUTHOR = {Jack Barkin, Shelley Burton, Carole Lambert},
TITLE = {Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {23},
YEAR = {2016},
NUMBER = {1},
PAGES = {8179--8183},
URL = {http://www.techscience.com/CJU/v23n1/61197},
ISSN = {1488-5581},
ABSTRACT = {The gonadotropin-releasing hormone (GnRH) receptor 
antagonist degarelix has several unique characteristics 
compared to luteinizing hormone-releasing hormone 
(LHRH) analogs used in the management of prostate 
cancer. Notable differences of GnRH receptor antagonists 
include no flare reaction, and a more rapid suppression 
of testosterone, luteinizing hormone (LH), follicle 
stimulating hormone (FSH) and prostate-specific 
antigen (PSA) compared to LHRH analogs. Despite 
emerging evidence supporting the use of GnRH receptor 
antagonists over the more widely used LHRH analogs in 
the management of prostate cancer, physicians may be 
reluctant to prescribe degarelix. They may be concerned 
about patient complaints about injection-site reactions 
(ISRs). The subcutaneous injection of degarelix has been 
associated with a higher rate of ISRs compared with the 
intramuscular injections of LHRH analogs. This “How 
I Do It” article describes techniques and strategies that 
have been developed by physicians and nurses to reduce 
the discomfort associated with the subcutaneous delivery 
of degarelix.},
DOI = {}
}